Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(83.3%)
Phase 2
1(16.7%)
6Total
N/A(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05443451Not ApplicableCompleted

BETTY: BEnign Prostatic Hyperplasia Transperineal Targeted Microwave therapY

Role: collaborator

NCT07412275Not ApplicableNot Yet Recruiting

Microwave Intervention Under Local Anesthesia

Role: lead

NCT05322356Not ApplicableActive Not Recruiting

Prostate Interstitial Brachytherapy With I125 Implant With Target Dose Supplementation in the Tumor Volume Guided by TRINITY® PERINE 3D System

Role: collaborator

NCT04627896Phase 2Completed

Targeted Microwave Focal Therapy

Role: collaborator

NCT04582656Not ApplicableUnknown

Efficacy Assessment of a Novel 3D Cartography-based Targeted Focal Microwave Therapy in Men With Localized Intermediate-risk Prostate Cancer

Role: lead

NCT04831905Not ApplicableUnknown

Micro-wave Ablation Under Organ-based Tracking in Patients With Prostate Cancer - FOSTINE

Role: collaborator

All 6 trials loaded